Our unique PDSP technology platform accelerates drug development.
BRIM accelerates drug development from preclinical to clinical proof of concept, targeting novel therapies for diseases with high unmet medical needs. Our projects are based on our proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform, which can be applied across multiple therapy areas and indications.
Novel therapies for diseases with high unmet medical needs.
Our lead asset, BRM421, is on track to become a first-in-class treatment for Dry Eye Syndrome (DES) which treats and repairs corneal damage. BRM421 is currently in Phase II/III clinical trials. We are also developing new drugs to treat severe corneal damage (BRM423) and osteoarthritis (BRM521), both of which are developed from our PDSP technology platform.
A potential first-in-class treatment for Dry Eye Syndrome (DES) which treats and repairs corneal damage.
Targeted to treat severe cornea damage which can lead to blindness.
Early-stage treatment in development for Neurotrophic Keratitis (NK), a rare, degenerative disease affecting the cornea.
Unique mechanism of action promotes joint cartilage regeneration and relieves pain caused by osteoarthritis.